Pfizer records 40% upside, defies the trend

Pfizer, a renowned biopharmaceutical company with a long history, has recently received an Equal-Weight recommendation from Wells Fargo, suggesting a potential upside of 40.53%. This recommendation is accompanied by a one-year price target averaging at $45.12, with a price range spanning from $32.32 to $78.75. As part of its financial outlook, Pfizer is projected to experience a 1.52% increase in annual revenue, reaching $79,124 million, with a non-GAAP EPS of 5.02.

Despite a recent decrease in institutional investment, Pfizer’s put/call ratio stands at 0.82, indicating a bullish outlook. The number of funds or institutions invested in Pfizer declined by 3.77% in the last quarter, with the average portfolio weight for PFE decreasing by 11.95% to 0.57%. Notable shareholders of the company include Wellington Management Group Llp and Capital World Investors, holding 4.13% and 3.52% of shares, respectively. Wellington increased its holdings by 6.08%, while Capital World reduced its stake by 16.33%. Other significant shareholders include Vanguard Total Stock Market Index Fund Investor Shares (3.12%), Vanguard 500 Index Fund Investor Shares (2.38%), and Geode Capital Management (2%).

Pfizer’s mission revolves around harnessing science and global resources to enhance lives worldwide, particularly in the field of healthcare. The company is dedicated to addressing and combatting severe diseases and collaborates with healthcare providers, governments, and local communities to extend access to reliable and affordable healthcare.

Pfizer maintains a commitment to transparency in its communication with stakeholders by consistently sharing investor information on its website, ensuring that investors and the public have access to relevant and up-to-date information about the company.